The Manufacturers Life Insurance Company Has $1.54 Million Position in Tyra Biosciences, Inc. $TYRA

The Manufacturers Life Insurance Company raised its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 381.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,224 shares of the company’s stock after purchasing an additional 31,867 shares during the quarter. The Manufacturers Life Insurance Company owned 0.07% of Tyra Biosciences worth $1,541,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in TYRA. Affinity Asset Advisors LLC acquired a new position in shares of Tyra Biosciences during the first quarter valued at about $9,863,000. Public Employees Retirement System of Ohio lifted its position in Tyra Biosciences by 10.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 20,522 shares of the company’s stock valued at $786,000 after acquiring an additional 1,980 shares in the last quarter. Walleye Capital LLC acquired a new position in Tyra Biosciences during the 1st quarter valued at about $717,000. Swiss National Bank bought a new stake in Tyra Biosciences during the 1st quarter worth approximately $1,011,000. Finally, Jennison Associates LLC bought a new stake in Tyra Biosciences during the 1st quarter worth approximately $24,222,000. 84.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TYRA has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Bank of America increased their price target on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Wolfe Research initiated coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective on the stock. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.90.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $26.25 on Tuesday. The firm’s 50-day simple moving average is $29.96 and its two-hundred day simple moving average is $32.66. Tyra Biosciences, Inc. has a 52 week low of $9.96 and a 52 week high of $40.65. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -10.94 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Analysts forecast that Tyra Biosciences, Inc. will post -2.72 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.